Flutamide — An antiandrogen inhibiting prostatic cancer and prostatic secretion with retention of potency

Springer Science and Business Media LLC - Tập 5 - Trang 61-65 - 1988
B. Stegmayr1, J. E. Johansson2, L. B. Schnürer3
1Department of Internal Medicine, University Hospital, Umeå, Sweden
2Department of Urology, County Hospital, Örebro, Sweden
3Department of Pathology, County Hospital, Örebro, Sweden

Tóm tắt

Ten men with prostatic cancer, stage T3M0 Nx or more, who were anxious to maintain sexual potency, were treated with flutamide. The eight metastasis-free tumours remained stable during treatment periods of 3–48 months. The two tumours with metastasis at the start of treatment showed growth inhibition for 3 and 7 months, respectively, but thereafter progressed, leacling to change of treatment. Nine of the ten men claimed maintained potency during flutamide therapy. Seven delivered ejaculate for biochemical analysis during or after flutamide therapy, as further evidence of potency. Biochemical analyses of the pre-flutamide ejaculates revealed higher values for markers of prostatic secretion in cases with high level of tumour differentiation. Significant reduction in the secreted amount of prostatic and seminal vesicle parameters was found in all the studied cases during flutamide therapy.

Tài liệu tham khảo

Geller J, Vazakas G, Fruchtman B, Newman H, Nakao K, Loh A: The effect of cyproterone acetate on advanced carcinoma of the prostate.Surg Gynec Obstet 127, 748 (1968). Jacobsson K: The determination of tartrate-inhibited phosphatase in serum.Scand J clin Lab Invest 12, 367 (1960). Lowry D H, Rosebrough N J, Farr A L, Randall R J: Protein measurement with the Folin phenol reagent.J biol Chem 193, 265(1951). Peets E, Henson F, Neri R, Tabachnick I: Effects of nonsteroidal antiandrogen SCH 13521 on testosterone disposition in rats.Fedn Proc Fedn Am Socs exp Biol 32, 759 (1973). Prout G R, Jr, Irwin R J, Jr, Kliman B, Daly J J, Mac-Laughlin R A, Griffin P P: Prostatic cancer and SCH-13521. II Histological alternations and the pituitary gonadal axis.J Urol 113, 834 (1975). Ronquist G, Gottfries A, Brody I, Stegmayr B: An Mg and Ca stimulated adenosine triphosphatase in human prostatic fluid. Parts I and II.Andrologia 10, 261, 427 (1978). Ronquist G, Stegmayr B: Prostatic origin of fucosyl-transferase in human seminal plasma. A study on healthy controls and on men with infertility or with prostatic cancer.Urol Res 12, 243 (1984). Sogani P C, Whitmore W F: Experience with flutamide in previously untreated patients with advanced prostatic cancer.J Urol 122, 640 (1979). Stegmayr B, Ronquist G, Kollberg H, Brody I: Analysis of ejaculates from patients with cystic fibrosis.Ultrastruct Path 2, 357 (1981). Stegmayr B, Busch C, Fritjofsson Å, Ronquist G: Biochemical and morphological studies of the prostate gland in men subjected to radical cystectomy.Uppsala J med Sci 90, 139 (1985). Varkarakis M J, Kirdani R Y, Yamanaka H, Murphy G P, Sandberg A A: Prostatic effects of a nonsteroidal antiandrogen.Invest Urol 12, 275 (1975). Zajicek J (1979) Aspiration biopsy cytology. Part 2. In Reed G (ed):Monographs in Clinical Cytology, vol. 7, pp. 145–152. Basel, S. Karger.